NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MEDICO · data 2026-10-31
Medico Remedies Ltd.
In plain words
Price: 67.3% below its 52-week high of ₹56.88.
Delivery: 69.4% of traded shares were kept for delivery over the last 10 sessions, against 56.4% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹238 cr |
| Net profit (last 12 months) | ₹14 cr |
| Sales growth, 3 years (yearly) | 13.4% |
| Profit growth, 3 years (yearly) | 21.9% |
At a glance
Promoters 61.4% (unchanged in a year), pledged 0.0%, institutions 0.6%.
P/E 11.2, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 19.0%, ROCE 20.4%, operating margin 6.1%: how much profit it earns on the money it uses.
Debt/equity 0.26, Profit growth 21.9% and sales growth 13.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (19.0%).
- Profit grew 21.9% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 63.3% over the last 20 sessions vs 48.5% in the 40 before (1.31x); shares delivered per day 0.36x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹1.19 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 25 Sept 26Deal Bulk deal: SAVITRIBEN MAHENDRAKUMAR SHAH sold ₹1.19 cr -31.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 61.38% | 61.38% | 61.38% | 61.38% |
| Foreign institutions (FII) | 0.60% | 0.08% | 0.03% | 0.49% |
| Domestic institutions (DII) | 0.00% | — | — | — |
| Mutual funds | 0.00% | — | — | — |
| Retail investors | 18.80% | 15.16% | 14.82% | 14.71% |
| Number of shareholders | 17,716 | 15,863 | 16,189 | 16,562 |
Common questions
How much do promoters hold in Medico Remedies Ltd.?
Promoters held 61.38% of Medico Remedies Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Medico Remedies Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.26.
What is Medico Remedies Ltd.'s P/E ratio?
About 11.2, based on the last 12 months' earnings and a price of ₹18.61 (data 2026-10-31).
What is the 52-week high and low of Medico Remedies Ltd.?
The 52-week high is ₹56.88 and the 52-week low is ₹18.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Medico Remedies Ltd. | ₹18.61 | ₹155 cr | 11.2 | — | 19% | 20.4% | 0.26 | -61.3% |
| Brooks Laboratories Limited | ₹60.56 | ₹179 cr | 13.5 | — | 22.3% | 4.8% | 0.07 | -43.3% |
| Curis Lifesciences Limited | ₹180 | ₹146 cr | 21.2 | 3.1 | 21.7% | 26.6% | 0.46 | +23.2% |
| Quest Laboratories Ltd. | ₹82 | ₹134 cr | 9 | 1.4 | 16.7% | 19.3% | 0.08 | -6.8% |
| Bal Pharma Limited | ₹81.85 | ₹129 cr | 18.1 | — | 7.9% | 19.2% | 2.03 | -2.4% |
| Krebs Biochemicals & Industries Ltd. | ₹56.6 | ₹126 cr | — | — | — | -17.3% | — | -18.6% |
Compare MEDICO with BROOKS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDICO in NSE Scanner →